Valuation : Exelixis, Inc.

Market Cap 13.49B 11.63B 10.9B 9.95B 18.75B 1,289B 18.8B 129B 50.46B 651B 50.65B 49.55B 2,158B P/E 2026 *
16.8x
P/E 2027 * 14.3x
Enterprise Value 12.75B 10.98B 10.3B 9.4B 17.71B 1,218B 17.77B 122B 47.67B 615B 47.86B 46.82B 2,039B EV / Sales 2026 *
5x
EV / Sales 2027 * 4.13x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 week+1.26%
Current month+1.92%
1 month-5.08%
3 months+5.58%
6 months+25.77%
Current year+22.91%
1 week 46.1
Extreme 46.095
48.7
1 month 43.19
Extreme 43.19
49.46
3 years 17.58
Extreme 17.58
50.57
5 years 13.96
Extreme 13.955
50.57
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%+3.76%+45.00%+129.36% 13.69B
-1.59%-3.35%+64.49%+98.69% 70.64B
-1.34%-0.75%+48.56%+90.63% 66.11B
-8.37%-12.43%+0.14%-15.42% 27.98B
-2.35%-5.75%-12.17%+448.29% 26.51B
+0.30%-0.69%+63.18%+11.93% 26.44B
-0.96%+10.36%+278.86%+438.78% 20.4B
-0.51%+0.23%+33.71%-18.02% 20.17B
-1.91%-4.37%+13.33%+531.29% 15.99B
-1.47%+0.68%+43.67%+145.49% 13.69B
Average -2.02%+0.19%+57.88%+186.10% 31.99B
Weighted average by Cap. -1.98%+0.11%+56.08%+151.12%

Financials

2026 *2027 *
Net sales 2.55B 2.2B 2.06B 1.88B 3.55B 244B 3.56B 24.46B 9.54B 123B 9.58B 9.37B 408B 2.87B 2.47B 2.32B 2.12B 3.99B 274B 4B 27.51B 10.74B 138B 10.78B 10.54B 459B
Net income 821M 707M 663M 605M 1.14B 78.43B 1.14B 7.87B 3.07B 39.59B 3.08B 3.01B 131B 974M 840M 787M 719M 1.35B 93.12B 1.36B 9.34B 3.64B 47.01B 3.66B 3.58B 156B
Net Debt -744M -642M -601M -549M -1.03B -71.15B -1.04B -7.14B -2.78B -35.92B -2.8B -2.73B -119B -1.62B -1.4B -1.31B -1.2B -2.25B -155B -2.26B -15.55B -6.07B -78.29B -6.09B -5.96B -260B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
-
Date Price Change
26-08-28 €46.95 -0.82%
26-08-27 €47.34 -1.96%
26-08-26 €48.29 -0.40%
26-08-25 €48.48 +3.50%
26-08-24 €46.84 +1.02%
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
54.45USD
Average target price
53.00USD
Spread / Average Target
-2.66%

Quarterly revenue - Rate of surprise